Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGA301A
- Development stage
- Preclinical
- Lead developer
- BMG Pharma
- Administration
- Intradermal
01
Overview
SGA301A is a preclinical-stage injectable dermal booster developed by BMG Pharma for applications in aesthetic medicine. Specifically designated as a "Booster Deep Dermis," the product is intended for injection into the deep dermal layers to enhance skin quality, hydration, and structural integrity. BMG Pharma focuses on innovative functional ingredients and delivery systems, often utilizing hyaluronic acid-based technologies for tissue regeneration and aesthetic enhancement. As a dermal booster, SGA301A is designed to revitalize the skin tissue rather than providing the immediate volume typical of traditional dermal fillers.
- Other names
- SGA301A Booster Deep DermisSGA-301A Booster Deep DermisSGA 301A Booster Deep Dermis
Beyond the preview
Go deeper on SGA301A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGA301A.